Symbols / ZURA
ZURA Chart
About
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 454.19M |
| Enterprise Value | 306.19M | Income | -62.52M | Sales | — |
| Book/sh | 1.67 | Cash/sh | 2.14 | Dividend Yield | — |
| Payout | 0.00% | Employees | 30 | IPO | — |
| P/E | — | Forward P/E | -11.84 | PEG | — |
| P/S | — | P/B | 4.20 | P/C | — |
| EV/EBITDA | -4.22 | EV/Sales | — | Quick Ratio | 5.45 |
| Current Ratio | 5.58 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.65 | EPS next Y | -0.59 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-24 | ROA | -27.24% |
| ROE | -45.01% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 65.02M |
| Shs Float | 26.23M | Short Float | 6.53% | Short Ratio | 4.22 |
| Short Interest | — | 52W High | 7.06 | 52W Low | 0.97 |
| Beta | 0.20 | Avg Volume | 609.94K | Volume | 769.77K |
| Target Price | $15.50 | Recom | Strong_buy | Prev Close | $6.69 |
| Price | $6.99 | Change | 4.41% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.50
Mean price target
2. Current target
$6.69
Latest analyst target
3. DCF / Fair value
$-7.79
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.69
Low
$10.00
High
$26.00
Mean
$15.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-09 | init | Wedbush | — → Outperform | $15 |
| 2025-11-14 | main | Chardan Capital | Buy → Buy | $10 |
| 2025-11-13 | init | Clear Street | — → Buy | $18 |
| 2025-09-30 | main | Chardan Capital | Buy → Buy | $10 |
| 2025-08-19 | main | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2025-08-15 | main | Oppenheimer | Outperform → Outperform | $16 |
| 2025-08-15 | main | Chardan Capital | Buy → Buy | $10 |
| 2025-05-09 | main | Oppenheimer | Outperform → Outperform | $17 |
| 2025-04-03 | main | HC Wainwright & Co. | Neutral → Neutral | $3 |
| 2025-03-26 | main | Oppenheimer | Outperform → Outperform | $19 |
| 2025-03-26 | reit | Guggenheim | Buy → Buy | $15 |
| 2025-03-26 | main | Chardan Capital | Buy → Buy | $10 |
| 2024-12-24 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-12-11 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2024-11-18 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-11-11 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-11-09 | main | Chardan Capital | Buy → Buy | $12 |
| 2024-11-04 | init | Leerink Partners | — → Outperform | $15 |
| 2024-10-21 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-10-18 | reit | Cantor Fitzgerald | — → Overweight | — |
- Biotech Zura Bio lines up $125M in share and warrant sale - Stock Titan Wed, 25 Feb 2026 11
- Zura Bio launches public offering of Class A shares - Investing.com ue, 24 Feb 2026 21
- Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - Stock Titan ue, 24 Feb 2026 21
- Zura Bio Strengthens Board with Immunology and R&D Leaders - TipRanks Mon, 23 Feb 2026 12
- Zura Bio And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance ue, 28 Oct 2025 07
- Zura Bio Stock Pre-Market (-3.6%): Phase 2 Trial Data Delayed to Q4 2026 - Trefis Sat, 24 Jan 2026 08
- Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit - Business Wire Wed, 04 Feb 2026 08
- ZURA BIO Earnings Preview: Recent $ZURA Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative Fri, 14 Nov 2025 08
- Does Zura Bio's (ZURA) Severance Plan Reflect Management's Priorities Amid Cash Burn Pressures? - simplywall.st Sat, 04 Oct 2025 07
- Zura's Make-or-Break Year Ahead: Will TibuSHIELD And TibuSURE Trials Deliver Or Disappoint? - Nasdaq ue, 07 Oct 2025 07
- Wedbush initiates coverage on Zura Bio stock with Outperform rating - Investing.com Mon, 09 Feb 2026 08
- Leaders behind four approved immunology drugs join Zura Bio board - Stock Titan Mon, 23 Feb 2026 11
- Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial Progress - Yahoo Finance Fri, 28 Nov 2025 08
- Zura Bio Advances Tibulizumab Strategy in Autoimmune Diseases - TipRanks Wed, 11 Feb 2026 08
- New Analyst Forecast: $ZURA Given $18.0 Price Target - Quiver Quantitative hu, 13 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1001633 | 2734458 | — | Sale at price 2.73 per share. | THIARA PARVINDER | Director | — | 2024-11-25 00:00:00 | I |
| 1 | 1500 | — | — | Stock Award(Grant) at price 0.00 per share. | DAVIS KIMBERLY ANN | Officer | — | 2024-09-16 00:00:00 | I |
| 2 | 3800000 | 13300000 | — | Sale at price 3.50 per share. | THIARA PARVINDER | Director | — | 2024-09-11 00:00:00 | I |
| 3 | 51728 | 200187 | — | Sale at price 3.87 per share. | SIDHU SOMEIT | Director | — | 2024-09-04 00:00:00 | D |
| 4 | 1557081 | — | — | Stock Award(Grant) at price 0.00 per share. | SIDHU SOMEIT | Director | — | 2024-08-23 00:00:00 | D/I |
| 5 | 126155 | — | — | Stock Award(Grant) at price 0.00 per share. | BADIAL VERENDER S | Chief Financial Officer | — | 2024-08-23 00:00:00 | D |
| 6 | 80000 | 496000 | — | Purchase at price 6.20 per share. | PLOOS VAN AMSTEL ARNOUT | Director | — | 2024-05-17 00:00:00 | D |
| 7 | 159744 | 499999 | — | Stock Award(Grant) at price 3.13 per share. | MUNSHI AMIT D | Director | — | 2024-04-22 00:00:00 | D |
| 8 | 159744 | 499999 | — | Purchase at price 3.13 per share. | MUNSHI AMIT D | Director | — | 2024-04-22 00:00:00 | D |
| 9 | 1186901 | 3715000 | — | Stock Award(Grant) at price 3.13 per share. | SIDHU SOMEIT | Director | — | 2024-04-22 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -49.94M | -64.75M | -27.16M |
| TotalUnusualItems | -5.24M | 2.12M | 6.22M |
| TotalUnusualItemsExcludingGoodwill | -5.24M | 2.12M | 6.22M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -52.40M | -60.36M | -25.74M |
| ReconciledDepreciation | 9.00K | 0.00 | |
| EBITDA | -55.18M | -62.64M | -27.16M |
| EBIT | -55.19M | -62.64M | -27.16M |
| NetInterestIncome | 8.00M | 2.19M | 8.00K |
| InterestIncome | 8.00M | 2.19M | 8.00K |
| NormalizedIncome | -47.16M | -62.48M | -25.74M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -52.40M | -60.36M | -25.74M |
| TotalExpenses | 55.19M | 62.64M | 27.16M |
| TotalOperatingIncomeAsReported | -55.19M | -62.64M | -27.16M |
| DilutedAverageShares | 75.07M | 33.06M | 2.11M |
| BasicAverageShares | 75.07M | 33.06M | 2.11M |
| DilutedEPS | -0.60 | -2.09 | -12.19 |
| BasicEPS | -0.60 | -2.09 | -12.19 |
| DilutedNIAvailtoComStockholders | -45.39M | -69.24M | -32.39M |
| NetIncomeCommonStockholders | -45.39M | -69.24M | -32.39M |
| OtherunderPreferredStockDividend | -7.02M | 8.88M | 6.65M |
| NetIncome | -52.40M | -60.36M | -25.74M |
| MinorityInterests | 0.00 | 203.00K | 1.59M |
| NetIncomeIncludingNoncontrollingInterests | -52.40M | -60.56M | -27.33M |
| NetIncomeContinuousOperations | -52.40M | -60.56M | -27.33M |
| TaxProvision | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -52.40M | -60.56M | -27.33M |
| OtherIncomeExpense | -5.21M | -111.00K | -179.00K |
| OtherNonOperatingIncomeExpenses | 28.00K | -2.23M | -179.00K |
| GainOnSaleOfSecurity | -5.24M | 2.12M | 6.22M |
| NetNonOperatingInterestIncomeExpense | 8.00M | 2.19M | 8.00K |
| InterestIncomeNonOperating | 8.00M | 2.19M | 8.00K |
| OperatingIncome | -55.19M | -62.64M | -27.16M |
| OperatingExpense | 55.19M | 62.64M | 27.16M |
| ResearchAndDevelopment | 24.40M | 44.00M | 23.69M |
| SellingGeneralAndAdministration | 30.79M | 18.64M | 3.47M |
| GeneralAndAdministrativeExpense | 30.79M | 18.64M | 3.47M |
| OtherGandA | 30.79M | 18.64M | 3.47M |
| TotalRevenue | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-03-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 65.30M | 43.59M | 27.05M | 26.55M |
| ShareIssued | 65.30M | 43.59M | 27.05M | 26.55M |
| NetDebt | 6.19M | |||
| TotalDebt | 7.76M | |||
| TangibleBookValue | 146.81M | 59.33M | -32.06M | -7.82M |
| InvestedCapital | 146.81M | 59.33M | -24.30M | -7.82M |
| WorkingCapital | 159.23M | 80.54M | -13.04M | 4.68M |
| NetTangibleAssets | 146.81M | 59.33M | -32.06M | -7.82M |
| CommonStockEquity | 146.81M | 59.33M | -32.06M | -7.82M |
| PreferredStockEquity | 12.50M | |||
| TotalCapitalization | 146.81M | 59.33M | -32.06M | -7.82M |
| TotalEquityGrossMinorityInterest | 160.02M | 79.55M | -22.06M | -7.82M |
| MinorityInterest | 13.20M | 20.22M | 10.00M | |
| StockholdersEquity | 146.81M | 59.33M | -32.06M | -7.82M |
| RetainedEarnings | -155.90M | -103.49M | -32.06M | -7.82M |
| AdditionalPaidInCapital | 302.70M | 162.82M | 0.00 | |
| CapitalStock | 7.00K | 4.00K | 0.00 | 0.00 |
| CommonStock | 7.00K | 4.00K | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 12.50M |
| TotalLiabilitiesNetMinorityInterest | 19.51M | 21.29M | 27.32M | 12.54M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 990.00K | 12.50M | 12.50M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 12.50M | 12.50M | |
| DerivativeProductLiabilities | 0.00 | 990.00K | 0.00 | 6.07M |
| NonCurrentDeferredLiabilities | 4.01M | 4.01M | ||
| CurrentLiabilities | 19.51M | 20.30M | 14.82M | 39.00K |
| OtherCurrentLiabilities | 2.63M | |||
| CurrentDebtAndCapitalLeaseObligation | 7.76M | |||
| CurrentDebt | 7.76M | |||
| CurrentNotesPayable | 0.00 | 7.76M | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.71M | 1.20M | 141.00K | |
| PayablesAndAccruedExpenses | 17.80M | 19.10M | 4.29M | 39.00K |
| CurrentAccruedExpenses | 17.07M | 16.35M | 2.28M | 199.56K |
| Payables | 733.00K | 2.75M | 2.01M | 72.73K |
| DuetoRelatedPartiesCurrent | 78.89K | 2.87K | ||
| AccountsPayable | 733.00K | 2.75M | 2.01M | 69.86K |
| TotalAssets | 179.53M | 100.84M | 5.26M | 4.72M |
| TotalNonCurrentAssets | 789.00K | 0.00 | 3.49M | 0.00 |
| OtherNonCurrentAssets | 698.00K | 141.47M | 139.40M | |
| NonCurrentDeferredAssets | 0.00 | 3.49M | ||
| NetPPE | 91.00K | 0.00 | ||
| CurrentAssets | 178.74M | 100.84M | 1.78M | 4.72M |
| OtherCurrentAssets | 2.25M | 1.04M | 209.00K | 422.89K |
| PrepaidAssets | 19.70K | 422.89K | ||
| CashCashEquivalentsAndShortTermInvestments | 176.50M | 99.81M | 1.57M | 4.72M |
| CashAndCashEquivalents | 176.50M | 99.81M | 1.57M | 4.72M |
| CashEquivalents | 97.91M | |||
| CashFinancial | 1.89M | 13.79K | 729.22K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| FreeCashFlow | -33.15M | -23.05M | -13.20M |
| RepaymentOfDebt | 0.00 | -10.00M | 0.00 |
| IssuanceOfDebt | 0.00 | 7.60M | |
| IssuanceOfCapitalStock | 60.76M | 116.41M | 10.00M |
| CapitalExpenditure | -5.08M | -8.00M | -12.00M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 176.50M | 99.81M | 1.57M |
| BeginningCashPosition | 99.81M | 1.57M | 0.00 |
| ChangesInCash | 76.69M | 98.24M | 1.57M |
| FinancingCashFlow | 109.84M | 121.29M | 14.77M |
| CashFlowFromContinuingFinancingActivities | 109.84M | 121.29M | 14.77M |
| NetOtherFinancingCharges | -944.00K | -1.18M | -2.83M |
| ProceedsFromStockOptionExercised | 50.03M | 16.07M | 0.00 |
| NetPreferredStockIssuance | 0.00 | 10.00M | |
| PreferredStockIssuance | 0.00 | 10.00M | |
| NetCommonStockIssuance | 60.76M | 116.41M | 0.00 |
| CommonStockIssuance | 60.76M | 116.41M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | -10.00M | 7.60M |
| NetShortTermDebtIssuance | 0.00 | -10.00M | 7.60M |
| ShortTermDebtPayments | 0.00 | -10.00M | 0.00 |
| ShortTermDebtIssuance | 0.00 | 7.60M | |
| NetLongTermDebtIssuance | -10.00M | 0.00 | |
| LongTermDebtPayments | -10.00M | 0.00 | |
| InvestingCashFlow | -5.08M | -8.00M | -12.00M |
| CashFlowFromContinuingInvestingActivities | -5.08M | -8.00M | -12.00M |
| NetIntangiblesPurchaseAndSale | -5.00M | -8.00M | -12.00M |
| PurchaseOfIntangibles | -5.00M | -8.00M | -12.00M |
| NetPPEPurchaseAndSale | -75.00K | 0.00 | |
| PurchaseOfPPE | -75.00K | 0.00 | |
| OperatingCashFlow | -28.08M | -15.05M | -1.20M |
| CashFlowFromContinuingOperatingActivities | -28.08M | -15.05M | -1.20M |
| ChangeInWorkingCapital | 2.31M | 5.12M | 3.54M |
| ChangeInOtherCurrentAssets | -698.00K | 0.00 | |
| ChangeInPayablesAndAccruedExpense | 4.21M | 5.94M | 3.75M |
| ChangeInAccruedExpense | 912.05K | ||
| ChangeInPayable | 288.29K | ||
| ChangeInAccountPayable | 288.29K | ||
| ChangeInPrepaidAssets | -1.21M | -828.00K | -209.00K |
| ChangeInReceivables | 0.00 | ||
| OtherNonCashItems | 29.23M | 22.08M | |
| StockBasedCompensation | 16.80M | 9.65M | 334.00K |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | 2.24M | 156.00K |
| DepreciationAmortizationDepletion | 9.00K | 0.00 | |
| DepreciationAndAmortization | 9.00K | 0.00 | |
| OperatingGainsLosses | 5.21M | -741.00K | 23.00K |
| GainLossOnInvestmentSecurities | 5.24M | -724.00K | -6.22M |
| NetForeignCurrencyExchangeGainLoss | -27.00K | -17.00K | 23.00K |
| NetIncomeFromContinuingOperations | -52.40M | -60.56M | -27.33M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ZURA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|